Mapping of breakpoints in balanced chromosomal translocations by shallow whole-genome sequencing points to EFNA5, BAHD1 and PPP2R5E as novel candidates for genes causing human Mendelian disorders

Background Mapping the breakpoints in de novo balanced chromosomal translocations (BCT) in symptomatic individuals provides a unique opportunity to identify in an unbiased way the likely causative genetic defect and thus find novel human disease candidate genes. Our aim was to fine-map breakpoints of de novo BCTs in a case series of nine patients. Methods Shallow whole-genome mate pair sequencing (SGMPS) together with long-range PCR and Sanger sequencing. In one case (BCT disrupting BAHD1 and RET ) cDNA analysis was used to verify expression of a fusion transcript in cultured fibroblasts. Results In all nine probands 11 disrupted genes were found, that is, EFNA5, EBF3, LARGE, PPP2R5E, TXNDC5, ZNF423, NIPBL, BAHD1, RET, TRPS1 and SLC4A10 . Five subjects had translocations that disrupted genes with so far unknown ( EFNA5, BAHD1, PPP2R5E, TXNDC5 ) or poorly delineated impact on the phenotype ( SLC4A10, two previous reports of BCT disrupting the gene). The four genes with no previous disease associations ( EFNA5, BAHD1, PPP2R5E, TXNDC5 ), when compared with all human genes by a bootstrap test, had significantly higher pLI (p EFNA5, BAHD1 and PPP2R5E were particularly good candidates for novel disease loci. The pathomechanism for BAHD1 may involve deregulation of expression due to fusion with RET promoter. Conclusion SGMPS in symptomatic carriers of BCTs is a powerful approach to delineate novel human gene–disease associations.